TY - JOUR
T1 - Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy
AU - Raj, Sibi
AU - Khurana, Sartaj
AU - Choudhari, Ramesh
AU - Kesari, Kavindra
AU - Kamal, Mohammad Amjad
AU - Garg, Neha
AU - Ruokolainen, Janne
AU - Das, Bhudev
AU - Kumar, Dhruv
N1 - Aseta tiedostolle embargo sitten kun julkaisu ilmestyy. Embargo 12 kk.
PY - 2021/2
Y1 - 2021/2
N2 - Nanotechnology has been the latest approach for diagnosis and treatment for cancer, which opens up a new alternative therapeutic drug delivery option to treat disease. Nanoparticles (NPs) display a broad role in cancer diagnosis and has various advantages over the other conventional chemotherapeutic drug delivery. NPs possess more specific and efficient drug delivery to the targeted tissue, cell, or organs and minimize the risk of side effects. NPs undergo passive and active mode of drug targets to tumor area with less elimination of the drug from the system. Size and surface characteristics of nanoparticles play a crucial role in modulating nanocarrier efficiency and the biodistribution of chemo drugs in the body. Several types of nanocarriers, such as polymers, dendrimers, liposome-based, and carbon-based, are studied widely in cancer therapy. Although FDA approved very few nanotechnology drugs for cancer therapy, a large number of studies are undergoing for the development of novel nanocarriers for potent cancer therapy. In this review, we discuss the details of the nano-based therapeutics and diagnostics strategies, and the potential use of nanomedicines in cancer therapy and cancer drug delivery.
AB - Nanotechnology has been the latest approach for diagnosis and treatment for cancer, which opens up a new alternative therapeutic drug delivery option to treat disease. Nanoparticles (NPs) display a broad role in cancer diagnosis and has various advantages over the other conventional chemotherapeutic drug delivery. NPs possess more specific and efficient drug delivery to the targeted tissue, cell, or organs and minimize the risk of side effects. NPs undergo passive and active mode of drug targets to tumor area with less elimination of the drug from the system. Size and surface characteristics of nanoparticles play a crucial role in modulating nanocarrier efficiency and the biodistribution of chemo drugs in the body. Several types of nanocarriers, such as polymers, dendrimers, liposome-based, and carbon-based, are studied widely in cancer therapy. Although FDA approved very few nanotechnology drugs for cancer therapy, a large number of studies are undergoing for the development of novel nanocarriers for potent cancer therapy. In this review, we discuss the details of the nano-based therapeutics and diagnostics strategies, and the potential use of nanomedicines in cancer therapy and cancer drug delivery.
UR - http://www.scopus.com/inward/record.url?scp=85075874792&partnerID=8YFLogxK
U2 - 10.1016/j.semcancer.2019.11.002
DO - 10.1016/j.semcancer.2019.11.002
M3 - Review Article
C2 - 31715247
VL - 69
SP - 166
EP - 177
JO - SEMINARS IN CANCER BIOLOGY
JF - SEMINARS IN CANCER BIOLOGY
SN - 1044-579X
ER -
